Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2006; 52(5): 80-91

Physiological aspects of ubiquinone supplementation under cardiovascularpathology

O.B. Kuchmenko

    Palladin Institute of Biochemistry of NAS of Ukraine



Abstract

Ubiquinone (coenzyme Q10</sub) is an obligatory component of the respiratory chain in the inner mitochondrial membrane coupled to ATP synthesis and acts as an antioxidant. Its addi- tional localization in the different subcellular fractions is prob- ably associated with its multiple functions in the cell. Coenzyme Q10 deficiency has been observed in patients with congestive heart failure, angina pectoris, coronary artery disease, cardi- omyopathy, hypertension, mitral valve prolapse. The clinical benefits of Q10 supplementation in prevention and treatment of cardiovascular diseases have been observed in many trials. Ubiquinone is the introduction of the metabolic drugs and may be recommended to patients with cardiovascular pathologies as an adjunct to conventional treatment.

Full text: (PDF, in Ukrainian)

References

  1. Антипенко А.Е., Калинский М.И., Лызлова С.Н. Метаболизм миокарда при различных функцио- нальных состояниях. – Екатеринбург: Изд-во Уральского ун-та, 1992. – 216 с.
  2. Аронов Д.М. Применение коэнзима Q10 в кардио- логической практике // Российский медиц. журн. – 2004. – Т.12, №15. – С.905–912.
  3. Донченко Г.В. Биохимия убихинона /Q/. – К.: Наук. думка, 1988. – 240 с.
  4. Донченко Г.В., Кучменко О.Б., Петухов Д.М. Біохімічні властивості і функціональна роль убіхінону (Q). Практичні аспекти застосування // Укр. біохім. журн. – 2005. – 70, №5. – С.24–36.
  5. Дриницина С.В., Затейщиков Д.А. Антиоксидантные свойства статинов // Кардиология. – 2005. – №4. – С.65–72.
  6. Жлоба А.А. Активные формы кислорода при сердечно-сосудистой патологии // Артериальная гипертензия. – 2000. – Т. 6, № 2. – С.59–67.
  7. Каган А.Х., Сыркин А.Л., Дриницина С.В. и др. Кислородные свободнорадикальные процессы в патогенезе ишемической болезни сердца и пер- спективы применения антиоксиданта коэнзима Q10 (убихинона) для их коррекции // Кардиология. – 1997. – Т. 37, № 12. – С. 67–73.
  8. Лакомкин В.Л., Коркина О.В., Цыпленкова В.Г. и др. Влияние гидрофильной формы убихинона на сердечную мышцу при окислительном стрессе // Там же. – 2004. – №1. – С.43–47.
  9. 9. Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Антиок- сиданты в комплексной терапии атеросклероза: pro et contra // Там же. – 2004. – №2. – С.72–81.
  10. 10. Ланкин В.З.Тихазе А.К., Беленков Ю.Н. Свободно- радикальные процессы при заболеваниях сердечно- сосудистой системы // Там же. – 2000. – №7. – С. 48–61.
  11. Мхітарян Л.С., Кучменко О.Б. Окислювальний стрес: механізми розвитку і роль в патології. – К.: ид-во НПУ ім.М.П. Драгоманова,2004. – 223 с.
  12. Писаренко О.И., Студнева И.М., Ланкин В.З. и др. Снижение энергообеспеченности миокарда при ведении крысам HMG – CoA – редуктазы // Бюл.эксперим. биологии и медицины. – 2001. – 132, №10. – С.401–403.
  13. Побежимова Т.П., Войников В.К. Биохимические и физиологические аспекты функционирования убихинона // Биол. мембр. – 1999. – 16, №5. – C. 485–491.
  14. Подколзин А.А., Донцов В.И., Крутько В.Н и др. Профилактика старения. Сообщение 1. индиви- дуальные вариации ферментов антиоксидантной системы организма и возможности её коррекции электрохимически активированными системами // Физиология человека. – 2002. – 28, №3. – С. 108–111.
  15. Серебров О. Роль коэнзима Q10 (убихинона) в профилактике и лечении заболеваний // Фармацев- тический вестник. – 2002. – №4(243). – С.35–37.
  16. Симоненко В.Б. Антиоксиданты в комплексной терапии инфаркта миокарда // Клиническая меди- цина. – 1998. – №11. – С.20–25.
  17. Физиология клеток миокарда. Физиология сердца. – Л.: Наука,1980. – 598 с.
  18. Хомазюк А.И., Гончар И.В. Энергетический метаболизм миокарда // Укр. кард. журн. – 2000. – №3. – С.88–95.
  19. 19.Школьникова М.А. Отчет Ассоциации детских кардиологов России по применению Кудесана // Применение антиоксидантного препарата кудесан (коэнзим Q10 с витамином Е) в кардиологии. – М., 2002. – С.23.
  20. 20. Aejmelaeus R., Mets-Ketel T., Laippala P. et al. Ubiquinol-10 and total peroxyl radical trapping capacity of LDL lipoproteins during aging: the effects of Q-10 supplementation // Molecular Aspects of Medicine. – 1997. – 18. – Р.І113–120.
  21. Battino M., Giunta S., Galezzi L. et al. Coenzyme Q10, antioxidant status and ApoE isoforms // Biofactors. – 2003. – 18, №1 – 4. – P.299–305.
  22. Burke B.E., Neuenschwander R., Olson R.D. Rando- mized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertention // South. Med.J. – 2001. – 91,№11. – P.1112–1117.
  23. Constantinescu A., Maguire J.J., Packer L. Interac- tions between ubiquinones and vitamins in membranes and cells // Molecular Aspects of Medicine. – 1994. – 15. – P.57–65.
  24. Crane F.L. Biochemical function of coenzyme Q10 // Journal of the American College of Nutrition. – 2001. – 20, № 6. – P.591–598.
  25. Crestanello J.A., Kamelgard J., Lingle D.M. et al. Elu- cidation of a tripartite mechanism underlying the improvement in cardiac tolerance to ischemia by coenzyme Q10 pretreatment // J. Thorac. Cardiovasc. Surg. – 1996. – 111, №2. – P.443–450.
  26. Folkers K., Langsjoen P.H., Willis R. et al. Lovastatin decreases coenzyme Q levels in humans // Proc Natl Acad Sci U S A. – 1990. – 87, №22. – P.8931–8934.
  27. Folkers K., Vadhanavikit S., Mortensen S.A. Biochemi- cal rationale and myocardial tissue data on the effec- tive therapy of cardiomyopathy with coenzyme Q10 // Proc Natl Acad Sci U S A. – 1985. – 82, №3. – P.901–904.
  28. Hamada M., Kazatani Y., Ochi T. et al. Correlation between serum CoQ10 level and myocardial contrac- tility in hypertensive patients // Biomedical and Clinical Aspects of Coenzyme Q, Elsevier, Amsterdam, 1984. – 4. – P.263–270.
  29. 29. Harker-Murray A.K., Tajik A.J., Ishikura F. et al. The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog // J. Card. Fail. – 2000. – 6, №3. – P. 233–242.
  30. 30. Heart disease. A Textbook of Cardiovascular Medicine / Edited by E.Braunwald. – Philadelphia:W.B.Saunders Company,1997. – 1996 p.
  31. Hiasa Y., Ishida T., Maeda T. et al. Effects of coenzyme Q10 on exercise tolerance in patients with stable angina pectoris / K.Folkers, Y.Yamamura (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam, 1984. – Vol.4. – P.291–301.
  32. Hodgson J.M., Watts G.F. Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress // Biofactors. – 2003. – 18, №1 – 4. – P.129– 136.
  33. Hodgson J.M., Watts G.H. et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes // Eur. Clin. Nutr. – 2002. – 56, №11. – P.1137–1142.
  34. Huss J.M., Kelly D.P. Mitochondrial energy metabo- lism in heart failure: a question of balance // J. Clinical Investigation. – 2005. – 115, №3. – P.547–555.
  35. Ishii N., Senoo-Matsuda N., Miyake K. Et al. Coenzyme Q10 can prolong C.elegans lifespan by owering oxidative stress // Mech. Ageing. De. – 2004. – 125, №1. – P.41–46.
  36. Kato T., Yoneda S., Kako T. et al. Reduction in blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease // Int. J. Clin. Pharmacol. Ther. Toxicol. – 1990. – 28, №3. – P.123–126.
  37. Kishimoto C., Tomioka N., Nakayama Y. et al. Anti- oxidant effects of coenzyme Q10 on experimental viral myocarditis in mice // J. Cardiovasc. Pharmacol. – 2003. – 42, №5. – P.588–592.
  38. Kontush A., Hubner C., Finckh B. et al. Antioxidative activity of ubiquinol-10 at physiologic concentrations in human low density lipoprotein // Biochim. Biophys. Acta. – 1995. – 1258, №2. – P.177–187.
  39. 39. Kuettner A., Pieper A., Koch J. et al. Influence of coenzyme Q(10) and cerivastatin on the flow-medi- ated vasodilation of the brachial artery: results of the ENDOTACT study // Int J. Cardiol. – 2005. – 98, №3. – P.413–419.
  40. 40. Langsjoen P.H., Folkers K. Isolated diastolic dysfunc- tion of the myocardium and its response to CoQ10 treat- ment / K.Folkers, S.A.Mortensen, G.P.Littarru, T.Yamagami, and G.Lenaz (eds) // Clinical. Investigator. – 1993. – 71. – P.140–144.
  41. Langsjoen P.H., Langsjoen A.M. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications // Biofactors. – 2003. – 18, № 1–4. – P.101–111.
  42. Langsjoen P.H., Langsjoen H.A., Willis R. et al. The Aging Heart: Reversal of Diastolic Dysfunction Through the Use of Oral CoQ10 in the Elderly. – In: Anti-Aging Medical Therapeutics. – Amsterdam: Health Quest Publications, 1997. – P.113–120.
  43. Langsjoen P.H., Langsjoen H.A., Willis R. et al. Treat- ment of essential hypertension with coenzyme Q10 // The Molecular Aspects of Medicine. – 1994. – 15. – P. 265–272.
  44. Langsjoen P.H., Langsjoen H.A., Willis R. et al. Treat- ment of Hypertrophic Cardiomyopathy with Coen- zyme Q10 // Molecular Aspects of Medicine. – 1997. – 18. – P. 145–151.
  45. Lenaz G. The role of mobility of redox components in the inner mitochondrial membrane // J. Membr. Biol. – 1988. – 104. – P.193–209.
  46. Miyake Y., Shouzu A., Nishikawa M. et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzume Q10 in dia- betic patients // Arzneimittelforschung. – 1999. – 49. – P.324–329.
  47. Morre D.M., Morre D.J. Specificity of coenzyme q inhibition of an aging-related cell surface NADH-oxi- dase (ECTO-NOX) that generates superoxide // Biofactors. – 2003. – 18, №1 – 4. – P.33–43.
  48. Mortensen S.A. Perspectives on therapy of cardio- vascular disease with coenzyme Q10 (ubiquinone) // Clin. Investig. – 1993. – 71. – P.116–123.
  49. 49. Mortensen S.A., Bouchelouche P., Muratsu K. et al. Clinical decline and relapse of cardiac patients on coenzyme Q10 withdrawal / K.Folkers and Y.Yamamura (eds) // Biomed. and Clin. Aspects of Coenzyme Q. Elsevier, Amsterdam, 1986. –Vol. 5. – P.281–290.
  50. 50. Mortensen S.A., Vadhanavikit S., Muratsu K. et al. Coenzyme Q10 : clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure // Int J. Tissue. React. – 1990. – 12, №3. – P.155–162.
  51. Murad N., Takiuchi K. et al. Coenzyme Q10 exogenous administration attenuates cold stress cardiac injury // Japn. Heart. J. – 2001. – 42, №3. – P.327–338.
  52. Nakamura T., Sanma H., Himeno M. et al. Transfer of exogenous coenzyme Q10 to the inner membrane of heart mitochondria in rats / K.Folkers, Y.Yamamura (eds) // Biomedical and Clinical Aspects of Coenzyme Q. Elsevier/ North-Holland Press, 1980. – Vol. 2. – P.3–14.
  53. Overvad K., Diamant B., Holm L. et al. Coenzyme Q10 in health and disease // Eur. J. Clin. Nutr. – 1999. – 53, №10. – P. 764–770.
  54. Palomaki A., Malminiemi K., Metsa-Ketela T. Enhanced oxidizability of ubiquinol and alpha-toco- pherol during lovastatin treatment // FEBS Letter. – 1997. – 410, №2–3. – P.254–258.
  55. Rauchova H., Lenaz G. Coenzyme Q and its therapeutic use // Ceska Slov Farm. – 2001. – 50, №2. – P.78–82.
  56. Rengo F., Abete P., Landino P. et al. Role of metabolic therapy in cardiovascular disease // Clin Investig. – 1993. – 71, №8. – P. 124–128.
  57. Richardson P., Drzewoski J., Ellis J. et al. Reduction of elevated blood pressure by coenzyme Q10 // Bio- medical and Clinical Aspects of Coenzyme Q, Elsevier, Amsterdam, 1981. – Vol. 3. – P.229–234.
  58. Rosenfeldt F., Hilton D., Pepe S. et al. Systematic review of effect of coenzyme Q10 in physical exercise, hypertention and heart failure // Biofactors. – 2003. – 18, №1 – 4. – P.91–100.
  59. 59. Rosenfeldt F., Marasco S., Lyon W. et al. Coenzyme Q10 therapy before cardiac surgery improves mitochon- drial function and in vitro contractility of myocardial tissue // J. Thorac. Cardiovasc. Surg. – 2005. – 129, №1. – P.25–32.
  60. 60. Sacher H.L., Sacher M.L., Landau S.W. et al. The clinical and hemodynamic effects of coenzyme Q10 in con- gestive cardiomyopathy // Amer. J. Therap. – 1997. – 4, №2 – 3. – P.66–72.
  61. Sarter B. Coenzyme Q10 and cardiovascular disease: a review // J. Cardiovasc. nurs. – 2002. – 16, №4. – P.9–20.
  62. Singh R.B., Niaz M.A. Serum concentration of lipoprotein(a) decreases on treatment with hydrsoluble coenzyme Q10 in patients with coronary artery dis- ease: discovery of a new role // Int. J. Cardiol. – 1999. – 68, №7. – P.23–29.
  63. Singh R.B., Niaz M.A., Rastogi et al. Coenzyme Q in cardiovascular disease // J. Assoc. Physicians. India. – 1998. – 46, №3. – P.299–306.
  64. Singh R.B., Niaz M.A., Rastogi S.S. et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease // J. Hum. Hypertens. – 1999. – 13, №3. – P.203–208.
  65. Singh R.B., Wander G.S., Rastogi A. et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction // Cardio- О.Б. Кучменко vasc. Drugs. Ther. – 1998. – 12, №4. – P. 347–353.
  66. Tanaka J., Tominaga R., Yoshitoshi M. et al. Coenzyme Q10 : the prophylactic effect on low cardiac output following cardiac valve replacement // Annals of Tho- racic Surgery. – 1982. – 33, №2. – P.145–151.
  67. Thomas S.R., Neuzil J., Stocker R. Cosupplementation with coenzyme Q prevents the prooxidant effect of alpha-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation // Arterioscler Thromb Vasc Biol. – 1996. – 16, №5. – P.687–696.
  68. Tsuyuasaki T., Noro C., Kikawada R. Mechano-cardiography of ischemic or hypertensive heart dis- ease / Y.Yamamura and K.Folkers (eds) // Biomedical and Clinical Aspects of Coenzyme Q – Elsevier, Amsterdam, 1980. – Vol. 2. – P.273–288.
  69. 69. Yamagami T., Takagi M., Akagami H. et al. Effect of coenzyme Q10 on essential hypertension, a double blind controlled study // Biomedical and Clinical Aspects of Coenzyme Q –0 Elsevier, Amsterdam, 1986. – Vol. 5. – P.337–343
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.